Stopping GLP-1 medications such as Ozempic can carry serious health consequences, according to reporting from Axios published on September 22, 2026. Axios reports that patients who discontinue these drugs may face elevated risks of heart attack and stroke.
The warning was echoed in related coverage. ScienceDaily reported that coming off Ozempic may raise the risk of heart attack and stroke, while The Sun described two potentially fatal conditions that can strike up to two years after a person stops using the treatments, which it referred to as fat jabs.
GLP-1 drugs have become widely used for weight loss and diabetes management. The reporting indicates that the dangers tied to stopping them are not necessarily immediate and may emerge well after a patient quits the medication. According to the coverage, the health threats can appear as long as two years following discontinuation.
The reports do not detail the specific medical mechanisms behind the delayed risks, and no further information on patient populations or study methods was included in the available material.
The takeaway from the coverage is that ending GLP-1 treatment is not a decision without consequences, and the period after stopping may be one of heightened vulnerability for cardiovascular events.
What to watch next: whether medical bodies or drug regulators issue formal guidance on how patients should taper off or monitor their health after stopping GLP-1 medications.
